MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention Atlanta, Georgia 30333

July 19, 2022

<u>A</u>	GENDA ITEM	PRESIDER/PRESENTER(s)
<u>Tuesday, July 19, 2022</u>		
10:00	Welcome & Introductions	Dr. Grace Lee (ACIP Chair)
		Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
	Coronavirus Disease 2019 (COVID-19) Vaccines	
10:15	Introduction	Dr. Matthew Daley (ACIP, WG Chair)
	Epidemiology of COVID-19 and COVID-19 Vaccine Coverage	Dr. Katherine Fleming-Dutra (CDC)
	Updates on vaccine-associated myocarditis	Dr. Tom Shimabukuro (CDC/NCEZID)
11:00	Break	
11:20	Novavax COVID-19 vaccine: Safety, immunogenicity and efficacy in adults	Dr. Filip Dubovsky (Novavax)
	ages 18 years and older	
12:20	Public Comment	
12:40	Break	
1:00	Novavax COVID-19 vaccine for adults: Evidence to Recommendations	Dr. Evelyn Twentyman (CDC/NCIRD)
	Clinical Considerations update	Dr. Elisha Hall (CDC/NCIRD)
	Discussion	
2:45	<u>VOTE</u>	
	Novavax COVID-19 vaccine in adults ages 18 years and older	Dr. Evelyn Twentyman (CDC/NCIRD)
3:00	Adjourn	
Acronyms		
CDC	Centers for Disease Control and Prevention	
CMS	Centers for Medicare and Medicaid Services	
COVID-19	Coronavirus disease 2019	
EtR	Evidence to Recommendations Framework	

FDA Food and Drug Administration

GRADE Grading of Recommendations Assessment, Development and Evaluation

HRSA Health Resources and Services Administration

IHS Indian Health Service

NCHHSTP National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID] National Center for Immunization & Respiratory Diseases [of CDC/OID] NCIRD NCEZID National Center for Emerging and Zoonotic Diseases [of CDC/OID]

NIAID National Institute of Allergy and Infectious Diseases Office of Infectious Disease and HIV/AIDS Policy OIDP SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2

WG Work Group

WHO World Health Organization

COVID-19 Vaccine Safety Technical (VaST) Work Group VaST

VE Vaccine Effectiveness